




argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands. LESS

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025 Estimate	2026 Estimate			
EPS EUR	-1.14	-1.14	-1.99	-4.22	-11.75	-6.76	-12.42	-4.77	12.87	13.39	21.00			
CASH FLOW/SHR EUR	0.57	-1.47	-1.57	3.63	-7.54	-10.01	-14.87	-5.30	0.41	Earnings Growth Rate	Sales Growth Rate			
PRETAX MARGIN %	-150%	-78%	-317%	-234%	-1,493%	-83%	-182%	-27%	2%	2023-25 --	2021-25 --			
RETURN ON EQUITY %	-43%	-14%	-15%	-21%	-44%	-19%	-28%	-9%	17%	2023-25 --	2021-25 --			
SALES % CHANGE	113%	148%	-41%	225%	-48%	1,062%	-7%	190%	79%	COMP RATING 95	SMR RATING A			
SALES (MIL) EUR	15	36	22	70	36	421	391	1,134	2,025	INV T/O 0.7x 31				
WEEKLY	Jul 11	Jul 18	Jul 25	Aug 1	Aug 8	Aug 15	Aug 22	Aug 29	Sep 3	DEBT %	2022-24	0.32%	0.37%	0.59%
DATAGRAPH RATING	45	45	42	61	63	54	62	66	68	TAX RATE	2022-24			-1699%
AVG DAILY VOL (000)	78	74	71	80	79	81	83	87	86	BACKLOG	2022-24			
UP/DOWN VOLUME	0.5	0.6	0.7	0.8	1.0	0.9	1.0	1.4	1.6	R & D	44.60%	BK VAL 6.98x '24		
ACCUM/DIST RATING	-34	-36	-7	13	8	-5	4	23	26	DIV EUR	None	DIV GR RT--		
RELATIVE STRENGTH	18	18	17	56	55	51	49	73	78	BETA	1.23(28.00)	ALPHA 0.06 (0.03)		
GROUP RANK	53	53	53	46	43	38	38	27	18	2024 EMPLOYEES	1,599	(39%)		

610.40 EUR

+6.40 +1.06%

600K

300K

213.1K

-19%